Core Insights - Incyte Corporation reported fourth-quarter 2025 adjusted earnings of $1.80 per share, missing the Zacks Consensus Estimate of $1.94 due to higher operating expenses [1][9] - Total revenues for the fourth quarter reached $1.51 billion, reflecting a 28% year-over-year growth, driven by strong performance of Jakafi and Opzelura, and exceeding the Zacks Consensus Estimate of $1.35 billion [2][9] Revenue Breakdown - Jakafi sales amounted to $828.2 million, a 7% increase from the previous year, driven by an 11% rise in paid demand, surpassing the Zacks Consensus Estimate of $800 million [3][9] - Opzelura cream generated $207.3 million in sales, up 28% year over year, exceeding the Zacks Consensus Estimate of $195.9 million due to increased patient demand [4][9] - Newly approved Zynyz generated $31.7 million in sales, significantly up from the previous year and beating the Zacks Consensus Estimate of $21.7 million [5] - Iclusig sales were $34.2 million, a 25% year-over-year increase, surpassing the Zacks Consensus Estimate of $30.7 million [5] - Pemazyre sales reached $23.4 million, reflecting a 1% year-over-year increase, also exceeding the Zacks Consensus Estimate of $22.9 million [5] - Minjuvi's revenues totaled $41.9 million, up 28% year over year, slightly beating the Zacks Consensus Estimate of $41.2 million [6] New Product Approvals - Incyte and Syndax Pharmaceuticals received FDA approval for axatilimab-csfr, branded as Niktimvo, for GVHD treatment, generating $56 million in sales in Q4 2025, a 22% sequential increase [7] Financial Performance - Adjusted R&D expenses were $575.2 million, up 37% year over year, primarily due to investments in late-stage development assets [13] - Adjusted SG&A expenses were $365.3 million, up 22% from the prior year, driven by costs associated with U.S. oncology product launches [13] - As of December 31, 2025, Incyte's cash, cash equivalents, and marketable securities totaled $3.6 billion, up from $2.9 billion as of September 30, 2025 [15] Full-Year Results and Guidance - For 2025, Incyte generated revenues of $5.14 billion, a 21% year-over-year growth, beating the Zacks Consensus Estimate of $4.97 billion [16] - The company expects Jakafi revenues in the range of $3.22-$3.27 billion for 2026, with Opzelura net product revenues projected between $750-$790 million [17]

分组1 - Incyte reported quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share, but showing an increase from $1.43 per share a year ago, resulting in an earnings surprise of -7.06% [1] - The company posted revenues of $1.51 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 12.02%, compared to year-ago revenues of $1.18 billion [2] - Incyte has outperformed the S&P 500, with shares increasing about 10.4% since the beginning of the year, while the S&P 500 gained 1.7% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $1.61 on revenues of $1.19 billion, and for the current fiscal year, it is $7.74 on revenues of $5.44 billion [7] - The Medical - Biomedical and Genetics industry, to which Incyte belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% year-over-year [5][30] - Net sales in Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [6][30] - GAAP R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [30] - GAAP SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% year-over-year [30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase versus 2024, with significant contributions from Opzelura, Niktimvo, and Monjuvi [6][10] - Jakafi sales in Q4 were $828 million, a 7% increase year-over-year, with full-year sales at $3.093 billion, an 11% increase [7] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10] Market Data and Key Metrics Changes - The U.S. market for Opzelura in atopic dermatitis (AD) is growing at nearly 20% year-over-year, while the vitiligo market is growing in the mid-teens [46] - The pediatric launch of Opzelura AD is annualizing around $30 million, indicating strong market uptake [9][46] - The international sales for Opzelura in vitiligo doubled to $130 million in 2025, with expectations for continued growth [9] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development, targeting MPNs, pancreatic cancer, colorectal cancer, and hidradenitis suppurativa (HS) [4][5] - The company anticipates significant growth in its core business, potentially matching Jakafi's current size by 2030, driven by upcoming product launches [13] - The company is focused on expanding its hematology portfolio and advancing novel therapies in myeloproliferative neoplasms [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a strong foundation for an inflection point in 2026 and beyond [5] - The company expects total revenues for 2026 to be between $4.77 billion and $4.94 billion, representing a 10%-13% increase from the prior year [32] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [35] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura for moderate AD, and povorcitinib for HS in Europe [5] - The company plans to initiate 14 pivotal trials across seven assets by the end of 2026, reflecting a robust pipeline [14][17] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management is discussing dosing strategies with the FDA to address differential potency across CALR mutations and is confident in their approach [39][40] Question: Opzelura uptake and average usage - The AD business is growing at nearly 20% year-over-year, with significant contributions from the pediatric launch and international markets [46][47] Question: Monjuvi's opportunity in front-line DLBCL - Monjuvi is positioned as an addition to R-CHOP, with a focus on a broad patient population, and management is optimistic about its competitive edge [54][55] Question: Opzelura in PN and FDA recommendations - The FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, but there is no read-through to HS [62][66] Question: Updates on mCALR bispecific and V617F programs - The mCALR bispecific program is accelerating, and management is optimistic about the V617F program's potential to address a significant patient population [72][75]

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [5][31] - Net sales for Q4 were $1.22 billion, representing a 20% increase year-over-year, and full-year net sales were $4.35 billion, also up 20% year-over-year [6][31] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [31] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% year-over-year [31] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion in 2025, a 53% increase compared to 2024, with significant contributions from OPZELURA, Niktimvo, and MONJUVI [6][10] - Jakafi sales in Q4 were $828 million, a 7% increase year-over-year, with full-year sales at $3.093 billion, an 11% increase [7] - OPZELURA's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10] Market Data and Key Metrics Changes - The U.S. market for OPZELURA in atopic dermatitis and vitiligo is expanding, with pediatric launches contributing to a strong start, annualizing around $30 million [9][46] - The international sales for OPZELURA in vitiligo doubled to $130 million in 2025, with expectations for continued growth [9] - The hematology and oncology business is projected to generate $800 million-$880 million in 2026, representing a 40%-50% increase compared to 2025 [13] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development, targeting MPNs, pancreatic cancer, colorectal cancer, and hidradenitis suppurativa [4][5] - The long-term goal is to nearly double the size of the core business excluding Jakafi by 2030, with significant growth expected from upcoming product launches [10][13] - The company is focused on expanding its pipeline with 14 pivotal trials across seven assets by the end of 2026, indicating a robust growth strategy [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a strong foundation for an inflection point in 2026 and beyond [5][6] - The company anticipates continued revenue growth driven by strong commercial performance and an increase in milestone and contract revenue [5][6] - Management emphasized the importance of execution in orchestrating product launches and managing multiple Phase III trials [35] Other Important Information - Regulatory applications for Jakafi XR, OPZELURA, and povorcitinib were submitted on time, enhancing visibility into the company's growth profile [5][6] - The company is exploring business development opportunities to extend and strengthen its core, with a focus on strategic fit and potential for durable revenue [15] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management is discussing dosing strategies with the FDA and is confident in their approach to address differential potency across mutations [39][40] Question: OPZELURA uptake and modeling sales - The AD business is growing at nearly 20% year-over-year, with significant contributions from pediatric launches and international markets [45][46] Question: MONJUVI's opportunity in front-line DLBCL - MONJUVI is positioned as an addition to R-CHOP, with a focus on addressing a broader patient population and competitive PFS benefits [52][54] Question: OPZELURA in prurigo nodularis and FDA recommendations - The FDA recommended an additional trial for OPZELURA in PN due to mixed results from previous studies, with no implications for HS [64][66] Question: mCALR bispecific and V617F program conviction - The mCALR bispecific program is accelerating, with a focus on differentiating it from current programs, while the V617F program is expected to generate promising data [73][75]

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [4][29] - Net sales for Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [5][29] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [29][30] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% [29][30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase from 2024, with expectations for over 30% growth in 2026 [5][12] - Jakafi sales in Q4 were $828 million, an increase of 7% year-over-year, with full-year sales at $3.093 billion, representing an 11% increase [6][29] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9][29] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10][29] Market Data and Key Metrics Changes - The pediatric launch of Opzelura for atopic dermatitis is performing well, with annualized sales around $30 million [9] - International sales for Opzelura in vitiligo doubled to $130 million in 2025 [9] - The hematology and oncology business is expected to generate $800-$880 million in 2026, representing a 40%-50% increase compared to 2025 [12][29] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development [3][4] - The focus is on expanding the core business, with expectations for product launches in late 2026 and early 2027 [12][14] - The company views business development as a multiplier to strengthen its core, with a focus on strategic fit and potential for durable revenue [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with a revenue guidance for 2026 set at $4.77 billion-$4.94 billion, a 10%-13% increase from the prior year [31][32] - The company anticipates a significant increase in core business growth, with expectations for Jakafi sales to be between $3.22 billion and $3.27 billion in 2026 [31] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [32] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura, and povorcitinib in Europe [4] - The pipeline has reached a new level of maturity, with 14 pivotal trials expected to be underway by the end of 2026 [15][16] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management indicated that they will discuss dosing strategies with the FDA and are confident in their approach [36][39] Question: Opzelura uptake and average usage - Management noted that the AD business is growing at nearly 20% year-over-year, with significant growth expected in the pediatric segment [42][45] Question: Monjuvi's opportunity in front-line DLBCL - Management highlighted that Monjuvi is positioned as an addition to R-CHOP, with a competitive PFS benefit [47][51] Question: Opzelura in PN and FDA recommendations - Management clarified that the FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, with no implications for HS [59][62] Question: mCALR bispecific and V617F program - Management expressed confidence in the mCALR bispecific program and the potential of the V617F program to deliver transformative clinical effects [64][68]

Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming patent losses on top-seller Jakafi. ...

03 R&D Highlights Pablo Cagnoni, MD | Head of R&D Alexis Smith | VP, Investor Relations 04 Financial Results Tom Tray | Principal Financial Officer 06 Q&A Fourth Quarter & Full-Year 2025 Financial & Corporate Update FEBRUARY 10, 2026 Agenda 01 Introduction Bill Meury | Chief Executive Officer 05 Closing Remarks Bill Meury | Chief Executive Officer Steven Stein, MD | EVP, Chief Medical Officer Dave Gardner | EVP, Chief Strategy Officer Mohamed Issa | EVP, Head of US Oncology 02 Opening Remarks Matteo Trotta ...

Financial Performance - Total revenue for Q4 2025 was $1.51 billion, a 28% increase year-over-year, and $5.14 billion for the full year 2025, a 21% increase year-over-year[1][6][7] - Total net product revenue for Q4 2025 was $1.22 billion, a 20% increase year-over-year, exceeding the full year 2025 guidance of $4.23 - $4.32 billion[1][7][11] - Total GAAP revenues for the quarter ended December 31, 2025, were $1.51 billion, representing a 28% increase compared to $1.18 billion in the same period of 2024[31] - Total net product revenues for the quarter increased 20% to $1.22 billion, driven by significant growth in Jakafi and Opzelura sales[32] - Product revenues for Q4 2025 reached $1,222.8 million, a 19.9% increase from $1,019.4 million in Q4 2024[75] - Total revenues for the twelve months ended December 31, 2025, were $5,141.2 million, up 21.3% from $4,241.2 million in 2024[75] - Net income for Q4 2025 was $299.3 million, a significant increase from $201.2 million in Q4 2024, representing a 48.8% growth[75] - Non-GAAP net income for Q4 2025 was $368.0 million, compared to $281.4 million in Q4 2024, marking a 30.7% increase[78] - Basic net income per share for Q4 2025 was $1.52, up from $1.04 in Q4 2024, reflecting a 46.2% increase[75] Revenue Guidance - Full year 2026 total net product revenue guidance is set at $4.77 - $4.94 billion, including Jakafi revenue of $3.22 - $3.27 billion and Opzelura revenue of $750 - $790 million[1][8][9] - Incyte's financial guidance for 2026 includes expectations for sales of Jakafi and Opzelura, along with anticipated revenue contributions from other hematology and oncology products like Niktimvo and Zynyz[71] Expenses - GAAP R&D expenses for the full year 2025 were $2.1 billion, a decrease of 21% compared to the prior year, while SG&A expenses were $1.4 billion, an increase of 11%[11] - Research and development expenses for Q4 2025 increased 31% to $611 million, primarily due to investments in late-stage development assets[37] - Selling, general, and administrative expenses for Q4 2025 rose 19% to $390 million, driven by costs associated with US oncology product launches[38] Cash and Assets - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $3.6 billion, up from $2.2 billion as of December 31, 2024[11] - Cash, cash equivalents, and marketable securities increased to $3,580.6 million as of December 31, 2025, up from $2,158.1 million in 2024[77] - Total assets grew to $6,958.0 million in 2025, a 27.7% increase from $5,444.3 million in 2024[77] - Stockholders' equity increased to $5,167.5 million in 2025, compared to $3,447.6 million in 2024, indicating a 49.9% growth[77] Clinical Trials and Regulatory Submissions - Incyte expects to have fourteen pivotal clinical trials underway by the end of 2025, reflecting strong pipeline progress[4] - The Company plans to file a supplemental Biologics License Application for tafasitamab in first-line DLBCL in the first half of 2026[12] - A regulatory decision for Jakafi XR is expected in mid-2026 following a response to the FDA's complete response letter[13] - The MAA for povorcitinib in hidradenitis suppurativa was submitted to the EMA at the end of 2025, with potential approval anticipated by the end of 2026[27] - Regulatory submissions and approvals are expected for Jakafi XR, Opzelura in Europe, Zynyz, Monjuvi, and povorcitinib[71] Product Highlights - Jakafi net product revenue for Q4 2025 was $828 million, a 7% increase year-over-year, with a total of $3.09 billion for the year, up 11%[32] - Opzelura net product revenue for Q4 2025 reached $207 million, a 28% increase, with annual revenue of $678 million, up 33%[32] - Jakafi is approved for multiple indications, including polycythemia vera and myelofibrosis, with a focus on patients who have had inadequate responses to other treatments[50] - Opzelura is the first and only treatment for repigmentation approved for nonsegmental vitiligo in the U.S., highlighting its unique market position[51] - Monjuvi has received accelerated approval for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma, expanding its therapeutic reach[56] - Pemazyre is approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, showcasing its targeted treatment capabilities[59] - Niktimvo is a first-in-class therapy for chronic GVHD, currently being studied in combination trials, indicating ongoing innovation in treatment options[68] Other Financial Metrics - The company recorded a contract dispute settlement of $242.2 million for the year, reflecting the difference between accrued royalties and total payments to Novartis[39] - An asset impairment charge of $76.3 million was recorded in Q4 2025 related to downtown Wilmington properties[40] - The company reported milestone revenues of $100.0 million for Q4 2025, compared to $0 in Q4 2024[78]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to find sustainable growth stocks [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988, outperforming the S&P 500 [7][8] - There are typically over 800 top-rated stocks available, making it essential for investors to utilize Style Scores for better selection [9] Stock to Watch: Incyte Corporation - Incyte Corporation, a biopharmaceutical company, is currently rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating solid potential [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 14, making it attractive to value investors [13] - Recent analyst revisions have increased earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising to $6.87 per share and an average earnings surprise of +14.4%, positioning Incyte as a noteworthy investment opportunity [13]

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed revenue and earnings estimates for Q4 2025, with projected revenues of $1.35 billion and earnings of $1.94 per share [2][6]. Revenue Drivers - The primary revenue source for Incyte is the sales of its lead drug, Jakafi (ruxolitinib), which is anticipated to continue its strong performance across all approved indications [3][4]. - Jakafi's fourth-quarter sales are estimated at $799.3 million, with additional royalty revenues expected from Novartis due to higher Jakavi sales outside the U.S. [4][6]. - Other contributing factors to revenue include growth in Opzelura sales, which are projected at $196.5 million, and sales from other drugs like Minjuvi, Pemazyre, and Iclusig [8][12]. Recent Developments - Incyte's recent approval of Monjuvi for a new cancer indication is likely to enhance its sales, with the drug also receiving approval in the EU and Japan [10][12]. - The launch of Niktimvo, which recorded $45.8 million in sales in Q3 2025, is another significant development for the company [13][14]. Financial Performance - Incyte's stock has increased by 31.4% over the past six months, compared to the industry growth of 43.5% [5]. - The company has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 14.35% [15]. Earnings Expectations - The Earnings Surprise Prediction model indicates a likelihood of an earnings beat for Incyte, with an Earnings ESP of +3.69% [16][17].